Coughlan JJ, Aytekin A, Lahu S, et al. - Findings demonstrate the superiority of a prasugrel-based strategy over a ticagrelor-based strategy for patients presenting with acute coronary syndrome (ACS) who receive percutaneous coronary intervention (PCI).

• In this prespecified subgroup analysis of a randomized clinical trial, safety and efficacy of ticagrelor vs prasugrel for patients with ACS treated with PCI was investigated.

• Patients were randomized to a ticagrelor-based (n=1676 patients) or prasugrel-based (n=1701) strategy.

• In the prasugrel group, less frequent occurrence of the composite endpoint of all-cause death, myocardial infarction, or stroke was evident vs the ticagrelor group (hazard ratio [HR], 1.41).

• Between the 2 groups, the incidence of bleeding events (safety endpoint) was comparable (HR; 1.10).